RBC Capital raised the firm’s price target on Insulet (PODD) to $365 from $350 and keeps an Outperform rating on the shares as part of a broader research note on MedTech ahead of Q3 results. There is broad interest in the Medical Supplies & Devices sector, with multiple opportunities across the landscape and attractive valuations with dislocations creating opportunities, the analyst tells investors in a research note. Sentiment for sentiment for Insulet is positive heading into the Q3 earnings season as the quarter is de-risked given that the company indicated they would be positioned to exceed their Q3 guidance due to the business momentum, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $399 from $353 at Canaccord
- Trump announces $15B libel suit against New York Times: Morning Buzz
- Trump announces $15 libel suit against New York Times: Morning Buzz
- Insulet Appoints New CFO Amid Revenue Growth
- Insulet expects to exceed Q3 revenue view of up 22%-25%